



**FOR IMMEDIATE RELEASE**

Contact: Joanne Westphal

202-572-7756

[jwestphal@phrma.org](mailto:jwestphal@phrma.org)

## **PhRMA Foundation Announces 2020 Value Assessment Research Award Recipients**

(June 3, 2020, Washington, D.C.) – The PhRMA Foundation announced today the recipients of its 2020 Value Assessment Research Awards. A total of \$300,000 was awarded to three teams whose proposals put forward new, innovative strategies for assessing the value of medicines and health care services.

This year’s winners will each receive one-year grants of \$100,000:

- **David D. Kim**, PhD of Tufts University School of Medicine and Tufts Medical Center
- **Lisa A. Prosser**, PhD of the University of Michigan Medical School
- **Wendy J. Ungar**, MS, PhD of The Hospital for Sick Children Research Institute

“This year’s Value Assessment Research Award recipients are just a small sample of the growing community of researchers whose work is moving the field of health care value assessment in the right direction,” said Eileen Cannon, President of the PhRMA Foundation. “We appreciate their dedication to improving the methods and measures used to determine the true value of health care treatments for myriad stakeholders.”

The Value Assessment Initiative aims to encourage more evidence-based research on how the true value of medicines can be accurately defined and quantified. It was launched in 2017 and includes the Foundation’s annual Research Awards, Challenge Awards and funding for the establishment of four national Centers of Excellence in Value Assessment. To date, the Foundation has awarded more than \$3.5 million to support a variety of research projects on value assessment.

Dr. Kim’s team seeks to develop a quality scoring system that can quantitatively capture both the methodology and reporting quality of cost-effectiveness analyses (CEA). This tool will help the value assessment research community advance its understanding of the quality of currently published CEAs to better identify available economic evidence of health care interventions.

Dr. Prosser's team is working to develop a preference-based index for the PedsQL scoring system, a common quality of life instrument used in clinical trials for pediatric health care interventions, that will allow for economic endpoints to be measured without the need for additional resource-intensive data collection.

Dr. Ungar's team aims to address the challenges of incorporating the benefits and costs of precision diagnostics to patients' family members —particularly genome sequencing—into economic evaluations of these treatments. Recognizing that precision medicine diagnosis also produces costs and health consequences for a patient's family members, her team aims to develop an evaluation framework with these factors included.

### **Apply for the 2021 Research Awards, Deadline Closes July 1, 2020**

The Foundation is proud to announce that the application process for the 2021 Value Assessment Research Awards is now open.

Award opportunities are open to all individuals and organizations with training in health economics, outcomes research, clinical sciences or health care evaluation. Eligible applicants should hold an advanced degree in a field of study logically or functionally related to the proposed activities, such as a PhD or equivalent. Interdisciplinary collaboration is highly encouraged. At least one collaborator must also have a firm commitment from an accredited U.S. university or research organization.

For more information about how to apply, please read the [PhRMA Foundation's Research Award brochure](#). Letters of intent (LOIs) are due by July 1, 2020.

###

### **About the PhRMA Foundation**

The mission of the PhRMA Foundation is to improve public health by proactively investing in innovative research, education and value-driven health care. For 55 years, the Foundation has been helping advance scientific research and innovation to benefit patients. Since its founding in 1965, it has distributed more than \$95 million to support these efforts. The PhRMA Foundation accomplishes its mission by investing in three key areas: core programming, value assessment initiative and a new program under development in the use and application of Data and Technology in Health Care. The PhRMA Foundation's core programs of Drug Delivery, Drug Discovery, Health Outcomes Research and Translational Medicine encourage young scientists to pursue research as their career choice and assists in training the next generation of innovators. The PhRMA Foundation's emphasis on evidence-based research that determines the true value of medicines is supported by its [Value Assessment Initiative](#). To learn more, please visit [www.phrmafoundation.org](http://www.phrmafoundation.org).